HTX-011
DrugDual-acting local anesthetic. Dose 1.
NCT Number: NCT03974932
Phase 3b, open-label single-arm study in which all subjects receive HTX-011 as part of a scheduled non-opioid MMA regimen.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Helen Keller Hospital, Sheffield, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dual-acting local anesthetic. Dose 1.
NSAID.
Analgesic.
NSAID.
Local anesthetic.
Applicator for instillation.
Time frame: 12 through 48 hours
The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
Time frame: 72 hours
The Visual Analog Scale (VAS) consists of a straight 10-cm line that represents pain ranging from "no pain" to "pain as bad as it could be". Subjects were asked to mark their current pain level on the line.
Time frame: 72 hours
Pain intensity scores are assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain". NRS scores are measured at rest.
Time frame: 24 hours, 48 hours, 72 hours
Severe Pain defined as a VAS score ≥7.5 cm.
Time frame: 72 hours
Time frame: 72 Hours to Day 11
Time frame: 72 hours through Day 11
Time frame: Through 72 hours
Time frame: 72 hours
Time frame: 72 hours through Day 11
Time frame: 24 hours, 48 hours, 72 hours, Day 11
Patient's Global Assessment (PGA) of pain control is a 4-point scale in which subjects rate how well their pain has been controlled (0 = Poor; 1 = Fair; 2 = Good; 3 = Excellent).
Time frame: 72 hours
Time frame: 72 hours
Time frame: 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24, hours, 36 hours, 48 hours, 60 hours, 72 hours
Subjects were assessed for readiness for discharge using the Modified Post-Anesthesia Discharge Scoring System (MPADSS) that assesses 5 clinical variables: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding, each on a 3-point scale of 0, 1, or 2 with 0 being the worst score and 2 being the best score. Subjects with an MPADSS score of 9 or 10 were considered ready for discharge.
Time frame: 72 hours
Number Analyzed represents Subjects who were discharged home.
Time frame: 24 hours, 48 hours, 72 hours, Day 11
Subjects were questioned about their overall benefit of analgesia. Overall benefit of analgesia score (OBAS) assesses current pain at rest, vomiting, itching, sweating, freezing, dizziness, and overall satisfaction with postoperative pain during the previous 24 hours. To calculate the OBAS score, each of the subscale scores (0=minimum; 4=maximum) are summed for a combined OBAS score. Possible scores could range from 0 to 28 with a lower score indicating greater benefit.
Time frame: 72 hours through Day 11
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) contains 9 items assessing Effectiveness, Convenience, and Global Satisfaction domains. Responses to items are rated on a 5-point or 7-point rating scale. Scores for each domain are computed by adding the TSQM items in each domain and then transforming the values in to a composite score ranging from 0 to 100, with higher scores representing higher satisfaction.
Time frame: 72 hours
Time frame: 72 hours
Heron Therapeutics
Industry
A Phase 3b, Open-Label Study of HTX-011 as Part of a Scheduled Non-Opioid Multimodal Analgesic Regimen in Subjects Undergoing Total Knee Arthroplasty
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07249827
Acute Pain, Agnosia
Montreal, Quebec, Canada
View Trial DetailsNCT04603638
Agnosia, Analgesia
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03907176
Agnosia, Analgesia
Anaheim, California, United States
View Trial DetailsNCT06282666
Acute Pain, Agnosia
Lublin, Poland
View Trial Details